Adverse cutaneous effects of mitogen-activated protein kinase inhibitors in children.

Recognizing skin toxicity in pediatric patients under treatment with MEKi is essential to establishing appropriate education and therapy, thereby improving treatment tolerability and minimizing avoidable interruptions in treatment.